Drug utilization pattern among type II diabetic patients in Palestine
- PMID: 40604765
- PMCID: PMC12225167
- DOI: 10.1186/s12913-025-13028-6
Drug utilization pattern among type II diabetic patients in Palestine
Abstract
Background: Diabetes mellitus is a common metabolic disorder marked by hyperglycemia. Studying the use of anti-diabetic medications is essential for promoting proper drug use and improving healthcare planning.
Objective: This study aims to examine the drug utilization patterns and prescribing practices among Type 2 Diabetic Patients in Palestine. Specifically, it seeks to identify the most commonly prescribed medications, evaluate adherence to clinical guidelines, and assess factors influencing drug utilization at diabetes healthcare centers operated by the Ministry of Health (MOH) in Palestine.
Methods: A cross-sectional survey was conducted among 400 randomly selected patients with T2DM attending diabetic clinics in the northern and central regions of the West Bank, Palestine. Data on prescribing patterns and medication adherence were collected through patient interviews, and ethical guidelines were strictly followed throughout the study.
Results: The study found that metformin was the most frequently prescribed initial therapy for patients with T2DM. Medication adherence was notably high, with 68% of patients consistently taking their medications as directed, although 24% reported occasionally forgetting to do so. Approximately 90% of patients followed the prescribed dosage exactly as instructed. There were no statistically significant differences in metformin prescribing patterns across the regions; prescriptions for glimepiride varied significantly (p = 0.01). Combination therapies were also commonly used.
Conclusion: This research can enhance our understanding of diabetes treatment methods, patient adherence, and the factors influencing prescription decisions. Ultimately, this will support the development of more effective strategies for diabetes management.
Keywords: Drug utilization review; Hyperglycemia; Oral hypoglycemic agents; Type 2 diabetes mellitus.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The procedures followed adhered to applicable guidelines and regulations. Before participating, each participant provided verbal informed consent was obtained from each participant. Approval was obtained from the Institutional Review Board (IRB) of An-Najah National University (under the number Mas.12.2020/1). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
References
-
- Balakumar P, Maung UK, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res. 2016;113(Pt A):600–9. - PubMed
-
- Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2020;162:108086. - PubMed
-
- Laher I. Diabetes and the Arab nations: have we reached a tipping point, and how do we silence the alarm? IEEE Pulse. 2014;5(3):26–9. - PubMed
-
- El Sharif N, Imam A. Current Status of Diabetes in Palestine: Epidemiology, Management, and Healthcare System. Handbook Health c Arab World. 2021:1053-81.